Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients
Background: The primary non-response (PNR) rate of infliximab (IFX) varies from 20 to 46% for the treatment of Crohn's disease (CD). Detected PNR reduces the improper use of specific treatments. To date, there is hardly any knowledge regarding early markers of PNR. The aim of this study was to...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | |
| Опубликовано: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Копировать 1 | Доступно |